IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
IONIS PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$44.38+1.44 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
IONIS PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and Development Revenue [Member] | $149.33M | $138.28M | $62.01M | $41.12M | $349.29M | $55.44M | $140.86M | $58.08M | $153.21M | $59.90M | $245.66M | $60.13M | 55.7% | -57.2% |
| Collaborative Agreement Revenue [Member] | $133.14M | $120.66M | $52.40M | $31.44M | $336.92M | $45.03M | $96.89M | $44.88M | $141.52M | $49.35M | $179.14M | $44.17M | 49.7% | -60.5% |
| Commercial Revenue [Member] | $118.62M | $107.81M | $141.33M | $115.60M | $102.76M | $76.17M | $85.72M | $75.73M | $72.04M | $59.59M | $78.85M | $84.08M | 44.3% | +15.4% |
| Royalty Revenue [Member] | $75.96M | $58.32M | $75.72M | $75.69M | $69.95M | $64.17M | $77.27M | $66.81M | $63.84M | $49.39M | – | – | 28.3% | +8.6% |
| SPINRAZA Royalties [Member] | $53.49M | $43.71M | $54.04M | $55.90M | $54.34M | $48.01M | $63.68M | $57.21M | $56.74M | $38.46M | $61.87M | $67.25M | 20.0% | -1.6% |
| Product Sales, Net [Member] | $31.14M | $42.96M | $57.96M | $31.79M | $19.27M | $6.29M | $0 | $0 | $0 | $0 | $9.49M | $8.29M | 11.6% | +61.6% |
| DAWNZERA Sales, Net [Member] | $26.57M | $15.86M | – | – | $0 | $0 | – | – | – | – | – | – | 9.9% | – |
| WAINUA Royalties [Member] | $16.44M | $10.71M | $15.98M | $13.32M | $10.42M | $9.37M | $9.93M | $5.37M | $3.78M | $1.13M | $0 | $0 | 6.1% | +57.8% |
| WAINUA Joint Development Revenue [Member] | $16.19M | $17.62M | $9.61M | $9.69M | $12.37M | $10.41M | $43.97M | $13.20M | $11.69M | $10.56M | $66.52M | $15.96M | 6.0% | +30.9% |
| Other Commercial Revenue [Member] | $11.53M | $6.53M | $7.65M | $8.11M | $13.53M | $5.72M | $8.45M | $8.92M | $8.19M | $10.21M | $16.98M | $16.83M | 4.3% | -14.8% |
| Other Royalties [Member] | $6.04M | $3.90M | $5.70M | $6.48M | $5.20M | $6.78M | $3.66M | $4.23M | $3.32M | $9.81M | – | – | 2.3% | +16.1% |
| TRYNGOLZA Sales, Net [Member] | $4.57M | $27.10M | – | $31.79M | $19.27M | $6.29M | – | $0 | $0 | $0 | – | – | 1.7% | -76.3% |
| Licensing and Other Royalty Revenue [Member] | – | – | – | – | – | – | – | $4.23M | $3.32M | $11.39M | $7.48M | $8.54M | – | – |
| Eplontersen Joint Development Revenue [Member] | – | – | – | – | – | – | – | – | – | – | – | $15.96M | – | – |
| Other Revenue [Member] | – | – | – | – | $0 | $0 | – | – | $0 | $1.58M | – | – | – | – |
| TEGSEDI and WAYLIVRA Revenue, Net [Member] | – | – | – | – | $13.53M | $5.72M | – | – | $8.19M | $8.63M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ionis Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.